Recent

% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • rubinstein.arno rubinstein.arno Jul 17, 2013 10:45 AM Flag

    OGXI-DD // 3 Blockbusters in Phase 3 Partnered with Teva Pharma // First Results in 4Q and 1Q 2014

    OGXI is an undiscovered Cancer Play with a Mega BLOCKBUSTER Pipeline ( 3x Phase 3 partnered with Pharma giant TEVA Pharma and another 6 candidates in Phase 2 ) .

    They have enough Cash untill late 2015 and a very Low Float of only 11 M shares .

    OncoGenex (OGXI)

    Market-Cap: $149 M
    Cash: $65 M
    NO Debt

    Shares Out : 14.7 M
    Fully Diluted : 17.7 M

    Emerging Leader in Next Generation Cancer Therapeutics

    Novel therapeutics that address mechanisms of treatment resistance in cancer

    Solid pipeline across multiple indications

    Custirsen in three Phase 3 trials

    SYNERGY prostate cancer death events for final analysis expected
    Q4 2013; data results expected to be announced H1 2014

    OGX-427 in seven randomized Phase 2 trials in four tumor types
    Key clinical catalysts across multiple late-stage programs:
    2013–2015

    Strong financial profile supports pipeline through 2015

    $64.6M in cash and investment securities as of 3/31/13

    Teva to fund all remaining custirsen expenses

    Custirsen

    Prostate Cancer
    Combination with 1st line chemotherapy (SYNERGY) in Phase 3 Teva partnership

    Combination with 2nd line chemotherapy (AFFINITY) in Phase 3 Teva partnership

    Non-Small Cell Lung Cancer
    Combination with 2nd line chemotherapy (ENSPIRIT) in Phase 3 Teva partnership

    OGX-427
    Unpartnered product candidate

    Bladder Cancer
    Superficial/muscle-invasive in Phase 1

    Combination with 1st Line Chemo (metastatic)(Borealis-1™) in Phase 2

    Combination with 2nd Line Chemo (metastatic)(Borealis-2™) in Phase 2

    Non-squamous non–small cell lung cancer
    Combination with 1st line chemotherapy (advanced)(Spruce™) in Phase 2

    Squamous non–small cell lung cancer
    Combination with 1st line chemotherapy (advanced) (Cedar™) in Phase 2

    Pancreatic cancer
    Combination with 1st line chemotherapy (metastatic) (Rainer™) in Phase 2

    Prostate Cancer
    Combination with prednisone (pre-chemo) in Phase 2
    Combination with abiraterone acetate (pre- or post-chemo) (Pacific™) in Phase 1

    OGX-225
    Solid Tumors in P

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
OGXI
2.28+0.12(+5.56%)May 27 4:00 PMEDT